Loading…
Reported covered position: Policy Director, Senate Majority Leader Mitch McConnell; Staff Director, Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant, Senator Don Nickles
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: AICPA ASSOCIATION OF INTERNATIONAL CERTIFIED PROFESSIONAL ACCOUNTANTS · Firm: MARSHALL & POPP, LLC
Issues related to the implementation of H.R. 1, the One Big Beautiful Bill Act (PL 119-21). Legislative proposals on tax simplification, tax reform, and technical tax changes.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: AICPA ASSOCIATION OF INTERNATIONAL CERTIFIED PROFESSIONAL ACCOUNTANTS · Firm: MARSHALL & POPP, LLC
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
VERTEX PHARMACEUTICALS INCORPORATED via MARSHALL & POPP, LLC
2026 · third_quarter · Q3
Issues related to tariff and trade policy.
Issues related to pain management, including S.475/H.R. 1227 - Alternatives to PAIN Act. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE, White House Office
Source: Senate LDA
| JAZZ PHARMACEUTICALS, INC. AND ITS SUBSIDIARIES, INCLUDING GREENWICH BIOSCIENCES |
| 31 |
| 2019–2026 |
| SANOFI U.S. SERVICES, INC. | 31 | 2019–2026 |
| AICPA ASSOCIATION OF INTERNATIONAL CERTIFIED PROFESSIONAL ACCOUNTANTS | 28 | 2020–2026 |
| PFIZER, INC. | 23 | 2021–2026 |
| GOOGLE CLIENT SERVICES LLC | 22 | 2021–2026 |
| 3M COMPANY | 21 | 2020–2024 |
| CITIZENS FOR RESPONSIBLE ENERGY SOLUTIONS | 19 | 2020–2024 |
| FORD MOTOR COMPANY | 18 | 2021–2025 |
| VERIZON COMMUNICATIONS INC. | 18 | 2022–2026 |
| ATLANTIC COAST CONFERENCE | 15 | 2020–2023 |
| PAC-12 CONFERENCE | 15 | 2020–2023 |
| SOUTHEASTERN CONFERENCE | 15 | 2020–2023 |
| THE BIG 12 CONFERENCE, INC. | 15 | 2020–2023 |
| THE BIG TEN CONFERENCE, INC. | 15 | 2020–2023 |
| FEDERATION OF AMERICAN HOSPITALS | 14 | 2023–2026 |
| JP MORGAN CHASE HOLDINGS, LLC | 14 | 2023–2026 |
| A PLACE FOR MOM, INC. | 13 | 2019–2022 |
| ABBVIE, INC. | 13 | 2023–2026 |
| ENTERTAINMENT SOFTWARE ASSOCIATION | 9 | 2021–2023 |
| ABBOTT LABORATORIES | 8 | 2025–2026 |
| ELI LILLY AND COMPANY | 8 | 2025–2026 |
| FGA ACTION, INC | 8 | 2025–2026 |
| GRAIL, Inc. | 8 | 2025–2026 |
| SAPPHIRE DIGITAL | 8 | 2019–2021 |
| VERTEX PHARMACEUTICALS INCORPORATED | 8 | 2025–2026 |
| BRIDGEBIO PHARMA | 7 | 2025–2026 |
| BUTTERFLY NETWORK, INC. | 7 | 2021–2022 |
| CSL BEHRING | 6 | 2025–2026 |
| HOUSE RX, INC. | 5 | 2024–2025 |
| BRISTOL-MYERS SQUIBB COMPANY | 4 | 2026 |
| DAIICHI SANKYO, INC. | 4 | 2026 |
| GLAXOSMITHKLINE | 4 | 2026 |
| NOVO NORDISK, INC. | 4 | 2019 |
| SUN PHARMACEUTICAL INDUSTRIES, INC. | 4 | 2026 |
| CURIE BIO OPERATIONS, LLC | 3 | 2026 |
Issues related to the implementation of H.R. 1, the One Big Beautiful Bill Act (PL 119-21). Legislative proposals on tax simplification, tax reform, and technical tax changes.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: AICPA ASSOCIATION OF INTERNATIONAL CERTIFIED PROFESSIONAL ACCOUNTANTS · Firm: MARSHALL & POPP, LLC
Issues related to the implementation of H.R. 1, the One Big Beautiful Bill Act (PL 119-21). Legislative proposals on tax simplification, tax reform, and technical tax changes, including H.R.5349, the Taxpayer Assistance and Service Act.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: MARSHALL & POPP, LLC
Issues related to pain management, including S.475/H.R. 1227 - Alternatives to PAIN Act. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: MARSHALL & POPP, LLC
Issues related to pain management, including S.475/H.R. 1227 - Alternatives to PAIN Act. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: MARSHALL & POPP, LLC
Issues related to pain management, including S.475/H.R. 1227 - Alternatives to PAIN Act. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to regulation of pharmaceuticals. H.R.1476-Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act).
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to regulation of pharmaceuticals. H.R.1476-Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act).
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to regulation of pharmaceuticals. H.R.1476-Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act).
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: MARSHALL & POPP, LLC
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: AMGEN USA INC. · Firm: MARSHALL & POPP, LLC
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R.1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: SANOFI U.S. SERVICES, INC. · Firm: MARSHALL & POPP, LLC
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: SANOFI U.S. SERVICES, INC. · Firm: MARSHALL & POPP, LLC
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PFIZER, INC. · Firm: MARSHALL & POPP, LLC
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: MARSHALL & POPP, LLC
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: AMGEN USA INC. · Firm: MARSHALL & POPP, LLC
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R.1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: AMGEN USA INC. · Firm: MARSHALL & POPP, LLC
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R.1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: MARSHALL & POPP, LLC
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: SANOFI U.S. SERVICES, INC. · Firm: MARSHALL & POPP, LLC
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PFIZER, INC. · Firm: MARSHALL & POPP, LLC
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: GENENTECH, INC. · Firm: MARSHALL & POPP, LLC
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PFIZER, INC. · Firm: MARSHALL & POPP, LLC
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: GENENTECH, INC. · Firm: MARSHALL & POPP, LLC
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: GENENTECH, INC. · Firm: MARSHALL & POPP, LLC
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
Humane Cosmetics Act of 2025
Client: PERSONAL CARE PRODUCTS COUNCIL · Firm: MARSHALL & POPP, LLC
Issues related to animal testing, including H.R.1657-Humane Cosmetics Act.
To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and for other purposes.
Client: ABBOTT LABORATORIES · Firm: MARSHALL & POPP, LLC
Issues related to infant formula, including H.R. 2300 - To ensure national uniformity with respect to certain requirements relating to preterm infant formula.
To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and for other purposes.
Client: ABBOTT LABORATORIES · Firm: MARSHALL & POPP, LLC
Issues related to infant formula, including H.R. 2300 - To ensure national uniformity with respect to certain requirements relating to preterm infant formula.
To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and for other purposes.
Client: ABBOTT LABORATORIES · Firm: MARSHALL & POPP, LLC
Issues related to infant formula, including H.R. 2300 - To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and S.4940 - Specialized Infant Formula Act.
Accounting STEM Pursuit Act of 2025
Client: AICPA ASSOCIATION OF INTERNATIONAL CERTIFIED PROFESSIONAL ACCOUNTANTS · Firm: MARSHALL & POPP, LLC
Issues related to defining accounting as STEM education, including H.R. 2911 - the Accounting STEM Pursuit Act.
Accounting STEM Pursuit Act of 2025
Client: AICPA ASSOCIATION OF INTERNATIONAL CERTIFIED PROFESSIONAL ACCOUNTANTS · Firm: MARSHALL & POPP, LLC
Issues related to defining accounting as STEM education, including H.R. 2911 - the Accounting STEM Pursuit Act.
Accounting STEM Pursuit Act of 2025
Client: AICPA ASSOCIATION OF INTERNATIONAL CERTIFIED PROFESSIONAL ACCOUNTANTS · Firm: MARSHALL & POPP, LLC
Issues related to defining accounting as STEM education, including H.R. 2911 - the Accounting STEM Pursuit Act.
Tackling Predatory Litigation Funding Act
Client: ABBOTT LABORATORIES · Firm: MARSHALL & POPP, LLC
H.R.3512 - Tackling Predatory Litigation Funding Act.
Tackling Predatory Litigation Funding Act
Client: ABBOTT LABORATORIES · Firm: MARSHALL & POPP, LLC
H.R.3512/S.1821 - Tackling Predatory Litigation Funding Act.
SPEED Act
Client: AIRPORTS COUNCIL INTERNATIONAL - NORTH AMERICA · Firm: MARSHALL & POPP, LLC
Issues related to airport infrastructure financing, and the use of fluorinated firefighting foam at airports. Issues related to air traffic control and facility upgrades. Issues related to airport safety, including S.2175 - Pilot and Aircraft Privacy Act, S.2503 - ROTOR Act, and H.R.7613 - ALERT Act. Issues related to federal permitting reform, including H.R.4776 - SPEED Act.
SPEED Act
Client: AIRPORTS COUNCIL INTERNATIONAL - NORTH AMERICA · Firm: MARSHALL & POPP, LLC
Issues related to airport infrastructure financing, and the use of fluorinated firefighting foam at airports. Issues related to air traffic control and facility upgrades. Issues related to airport safety, including S.2175 - Pilot and Aircraft Privacy Act, S.2503 - ROTOR Act, and H.R.7613 - ALERT Act. Issues related to federal permitting reform, including H.R.4776 - SPEED Act.
SPEED Act
Client: AIRPORTS COUNCIL INTERNATIONAL - NORTH AMERICA · Firm: MARSHALL & POPP, LLC
Issues related to airport infrastructure financing, and the use of fluorinated firefighting foam at airports. Issues related to air traffic control and facility upgrades. Issues related to airport safety, including S.2175 - Pilot and Aircraft Privacy Act, S.2503 - ROTOR Act, and H.R.7613 - ALERT Act. Issues related to federal permitting reform, including H.R.4776 - SPEED Act.
TAS Act
Client: AICPA ASSOCIATION OF INTERNATIONAL CERTIFIED PROFESSIONAL ACCOUNTANTS · Firm: MARSHALL & POPP, LLC
Issues related to the implementation of H.R. 1, the One Big Beautiful Bill Act (PL 119-21). Legislative proposals on tax simplification, tax reform, and technical tax changes, including H.R.5349, the Taxpayer Assistance and Service Act.
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
Consolidated Appropriations Act, 2026
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: MARSHALL & POPP, LLC
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
Consolidated Appropriations Act, 2026
Client: SANOFI U.S. SERVICES, INC. · Firm: MARSHALL & POPP, LLC
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
Issues related to cancer screening, including the implementation of Section 6221 of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75.
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R.1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
Issues related to cancer screening, including the implementation of Section 6221 of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75.
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
ALERT Act
Client: AIRPORTS COUNCIL INTERNATIONAL - NORTH AMERICA · Firm: MARSHALL & POPP, LLC
Issues related to airport infrastructure financing, and the use of fluorinated firefighting foam at airports. Issues related to air traffic control and facility upgrades. Issues related to airport safety, including S.2175 - Pilot and Aircraft Privacy Act, S.2503 - ROTOR Act, and H.R.7613 - ALERT Act. Issues related to federal permitting reform, including H.R.4776 - SPEED Act.
ALERT Act
Client: AIRPORTS COUNCIL INTERNATIONAL - NORTH AMERICA · Firm: MARSHALL & POPP, LLC
Issues related to airport infrastructure financing, and the use of fluorinated firefighting foam at airports. Issues related to air traffic control and facility upgrades. Issues related to airport safety, including S.2175 - Pilot and Aircraft Privacy Act, S.2503 - ROTOR Act, and H.R.7613 - ALERT Act. Issues related to federal permitting reform, including H.R.4776 - SPEED Act.
ALERT Act
Client: AIRPORTS COUNCIL INTERNATIONAL - NORTH AMERICA · Firm: MARSHALL & POPP, LLC
Issues related to airport infrastructure financing, and the use of fluorinated firefighting foam at airports. Issues related to air traffic control and facility upgrades. Issues related to airport safety, including S.2175 - Pilot and Aircraft Privacy Act, S.2503 - ROTOR Act, and H.R.7613 - ALERT Act. Issues related to federal permitting reform, including H.R.4776 - SPEED Act.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Drug Competition Enhancement Act
Client: SANOFI U.S. SERVICES, INC. · Firm: MARSHALL & POPP, LLC
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Drug Competition Enhancement Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: MARSHALL & POPP, LLC
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Drug Competition Enhancement Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: MARSHALL & POPP, LLC
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Drug Competition Enhancement Act
Client: SANOFI U.S. SERVICES, INC. · Firm: MARSHALL & POPP, LLC
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Drug Competition Enhancement Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: MARSHALL & POPP, LLC
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Drug Competition Enhancement Act
Client: SANOFI U.S. SERVICES, INC. · Firm: MARSHALL & POPP, LLC
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Affordable Prescriptions for Patients Act
Client: SANOFI U.S. SERVICES, INC. · Firm: MARSHALL & POPP, LLC
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Affordable Prescriptions for Patients Act
Client: SANOFI U.S. SERVICES, INC. · Firm: MARSHALL & POPP, LLC
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Affordable Prescriptions for Patients Act
Client: GENENTECH, INC. · Firm: MARSHALL & POPP, LLC
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Affordable Prescriptions for Patients Act
Client: GENENTECH, INC. · Firm: MARSHALL & POPP, LLC
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Affordable Prescriptions for Patients Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: MARSHALL & POPP, LLC
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Affordable Prescriptions for Patients Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: MARSHALL & POPP, LLC
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Affordable Prescriptions for Patients Act
Client: SANOFI U.S. SERVICES, INC. · Firm: MARSHALL & POPP, LLC
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Affordable Prescriptions for Patients Act
Client: GENENTECH, INC. · Firm: MARSHALL & POPP, LLC
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Affordable Prescriptions for Patients Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: MARSHALL & POPP, LLC
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Issues related to the World Trade Organization and digital trade rules. S.1705 - Chip Security Act.
Issues related to the World Trade Organization and digital trade rules. S.1705 - Chip Security Act.
Issues related to the World Trade Organization and digital trade rules. S.1705 - Chip Security Act.
Tackling Predatory Litigation Funding Act
Client: ABBOTT LABORATORIES · Firm: MARSHALL & POPP, LLC
H.R.3512/S.1821 - Tackling Predatory Litigation Funding Act.
Pilot and Aircraft Privacy Act
Client: AIRPORTS COUNCIL INTERNATIONAL - NORTH AMERICA · Firm: MARSHALL & POPP, LLC
Issues related to airport infrastructure financing, and the use of fluorinated firefighting foam at airports. Issues related to air traffic control and facility upgrades. Issues related to airport safety, including S.2175 - Pilot and Aircraft Privacy Act, S.2503 - ROTOR Act, and H.R.7613 - ALERT Act. Issues related to federal permitting reform, including H.R.4776 - SPEED Act.
Pilot and Aircraft Privacy Act
Client: AIRPORTS COUNCIL INTERNATIONAL - NORTH AMERICA · Firm: MARSHALL & POPP, LLC
Issues related to airport infrastructure financing, and the use of fluorinated firefighting foam at airports. Issues related to air traffic control and facility upgrades. Issues related to airport safety, including S.2175 - Pilot and Aircraft Privacy Act, S.2503 - ROTOR Act, and H.R.7613 - ALERT Act. Issues related to federal permitting reform, including H.R.4776 - SPEED Act.
Pilot and Aircraft Privacy Act
Client: AIRPORTS COUNCIL INTERNATIONAL - NORTH AMERICA · Firm: MARSHALL & POPP, LLC
Issues related to airport infrastructure financing, and the use of fluorinated firefighting foam at airports. Issues related to air traffic control and facility upgrades. Issues related to airport safety, including S.2175 - Pilot and Aircraft Privacy Act, S.2503 - ROTOR Act, and H.R.7613 - ALERT Act. Issues related to federal permitting reform, including H.R.4776 - SPEED Act.
Issues related to airport infrastructure financing, and the use of fluorinated firefighting foam at airports. Issues related to air traffic control and facility upgrades. Issues related to airport safety, including S.2175 - Pilot and Aircraft Privacy Act, S.2503 - ROTOR Act, and H.R.7613 - ALERT Act. Issues related to federal permitting reform, including H.R.4776 - SPEED Act.
Issues related to airport infrastructure financing, and the use of fluorinated firefighting foam at airports. Issues related to air traffic control and facility upgrades. Issues related to airport safety, including S.2175 - Pilot and Aircraft Privacy Act, S.2503 - ROTOR Act, and H.R.7613 - ALERT Act. Issues related to federal permitting reform, including H.R.4776 - SPEED Act.
Issues related to airport infrastructure financing, and the use of fluorinated firefighting foam at airports. Issues related to air traffic control and facility upgrades. Issues related to airport safety, including S.2175 - Pilot and Aircraft Privacy Act, S.2503 - ROTOR Act, and H.R.7613 - ALERT Act. Issues related to federal permitting reform, including H.R.4776 - SPEED Act.
A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests.
Client: GRAIL, INC. · Firm: MARSHALL & POPP, LLC
Issues related to cancer screening, including S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: MARSHALL & POPP, LLC
Issues related to pain management, including S.475/H.R. 1227 - Alternatives to PAIN Act. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: MARSHALL & POPP, LLC
Issues related to pain management, including S.475/H.R. 1227 - Alternatives to PAIN Act. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: MARSHALL & POPP, LLC
Issues related to pain management, including S.475/H.R. 1227 - Alternatives to PAIN Act. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
Specialized Infant Formula Protection Act
Client: ABBOTT LABORATORIES · Firm: MARSHALL & POPP, LLC
Issues related to infant formula, including H.R. 2300 - To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and S.4940 - Specialized Infant Formula Act.
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
Client: GENENTECH, INC. · Firm: MARSHALL & POPP, LLC
Issues related to budget reconciliation, including H.Con.Res. 14 and S.Con.Res. 7.
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
Client: SANOFI U.S. SERVICES, INC. · Firm: MARSHALL & POPP, LLC
Issues related to budget reconciliation, including H.Con.Res. 14.
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
Client: VERIZON COMMUNICATIONS, INC. · Firm: MARSHALL & POPP, LLC
Issues related to budget reconciliation, including H.Con.Res. 14 and S.Con.Res. 7.
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
Client: AMGEN USA INC. · Firm: MARSHALL & POPP, LLC
Issues related to budget reconciliation, including H.Con.Res. 14 and S.Con.Res. 7.
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
Client: GENENTECH, INC. · Firm: MARSHALL & POPP, LLC
Issues related to budget reconciliation, including H.Con.Res. 14 and S.Con.Res. 7.
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: MARSHALL & POPP, LLC
Issues related to budget reconciliation, including H.Con.Res. 14 and S.Con.Res. 7.
SUN PHARMACEUTICAL INDUSTRIES, INC. via MARSHALL & POPP, LLC
2026 · third_quarter · Q3
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SANOFI U.S. SERVICES, INC. via MARSHALL & POPP, LLC
2026 · third_quarter · Q3
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
Issues related to vaccine excise taxes and the Vaccine Injury Compensation Fund.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Issues related to tariff and trade policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via MARSHALL & POPP, LLC
2026 · third_quarter · Q3
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
Issues related to tariff and trade policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE
PFIZER, INC. via MARSHALL & POPP, LLC
2026 · third_quarter · Q3
Issues related to tariff and trade policy.
Issues related to vaccine excise taxes and the Vaccine Injury Compensation Fund.
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE
PERSONAL CARE PRODUCTS COUNCIL via MARSHALL & POPP, LLC
2026 · third_quarter · Q3
Issues related to regulation of cosmetics, including sunscreen regulation and the implementation of the Modernization of Cosmetics Regulation Act as enacted as part of the Consolidated Appropriations Act (PL 117-328). Issues related to the regulation of over-the-counter products.
Issues related to animal testing, including H.R.1657-Humane Cosmetics Act.
Issues related to regulation of cosmetics, including the implementation of the Modernization of Cosmetics Regulation Act as enacted as part of the Consolidated Appropriations Act (PL 117-328).
JP MORGAN CHASE HOLDINGS, LLC via MARSHALL & POPP, LLC
2026 · third_quarter · Q3
Issues related to electronic credit transaction processing.
Filing targets: SENATE
JAZZ PHARMACEUTICALS, INC. AND ITS SUBSIDIARIES, INCLUDING GREENWICH BIOSCIENCES via MARSHALL & POPP, LLC
2026 · third_quarter · Q3
Issues related to tariff and trade policy.
Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the regulation of hemp-derived cannabinoids.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE
GRAIL, INC. via MARSHALL & POPP, LLC
2026 · third_quarter · Q3
Issues related to cancer screening, including the implementation of Section 6221 of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GOOGLE CLIENT SERVICES LLC via MARSHALL & POPP, LLC
2026 · third_quarter · Q3
Regulation of online advertising.
Issues related to permitting reform and data centers.
Issues related to the World Trade Organization and digital trade rules. S.1705 - Chip Security Act.
GLAXOSMITHKLINE via MARSHALL & POPP, LLC
2026 · third_quarter · Q3
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the 340B program. Issues related to FDA regulation of pharmaceuticals.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENENTECH, INC. via MARSHALL & POPP, LLC
2026 · third_quarter · Q3
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
FGA ACTION, INC via MARSHALL & POPP, LLC
2026 · third_quarter · Q3
Issues related to the federal budget.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FEDERATION OF AMERICAN HOSPITALS via MARSHALL & POPP, LLC
2026 · third_quarter · Q3
Issues related to the extension of enhanced Affordable Care Act insurance subsidies.
Issues related to Medicaid funding. Issues related to site-neutral payment policies and hospital price transparency provisions. Issues related to health care cybersecurity, rural health extenders, telehealth and drug shortages.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via MARSHALL & POPP, LLC
2026 · third_quarter · Q3
Issues related to treatments for Alzheimers therapeutics.
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. Issues related to the 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DAIICHI SANKYO, INC. via MARSHALL & POPP, LLC
2026 · third_quarter · Q3
Issues related to tariff and trade policy.
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE
CSL BEHRING via MARSHALL & POPP, LLC
2026 · third_quarter · Q3
Issues related to tariff and trade policy.
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to regulation of pharmaceuticals. H.R.1476-Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act).
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE
BRISTOL-MYERS SQUIBB COMPANY via MARSHALL & POPP, LLC
2026 · third_quarter · Q3
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the 340B program. Issues related to FDA regulation of pharmaceuticals.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRIDGEBIO PHARMA via MARSHALL & POPP, LLC
2026 · third_quarter · Q3
Issues related to pharmaceutical manufacturing, drug pricing, and orphan drugs. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AMGEN USA INC. via MARSHALL & POPP, LLC
2026 · third_quarter · Q3
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R.1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
ALTRIA CLIENT SERVICES via MARSHALL & POPP, LLC
2026 · third_quarter · Q3
Discussions regarding the FDAs need to urgently implement a compliance and enforcement plan to address and prohibit the importation and sale of illicit flavored, disposable electronic nicotine delivery system (ENDS) products. Issues related to federal excise taxes and the taxation of tobacco products. Issues related to FDA approval of tobacco products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AIRPORTS COUNCIL INTERNATIONAL - NORTH AMERICA via MARSHALL & POPP, LLC
2026 · third_quarter · Q3
Issues related to airport infrastructure financing, and the use of fluorinated firefighting foam at airports. Issues related to air traffic control and facility upgrades. Issues related to airport safety, including S.2175 - Pilot and Aircraft Privacy Act, S.2503 - ROTOR Act, and H.R.7613 - ALERT Act. Issues related to federal permitting reform, including H.R.4776 - SPEED Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AICPA ASSOCIATION OF INTERNATIONAL CERTIFIED PROFESSIONAL ACCOUNTANTS via MARSHALL & POPP, LLC
2026 · third_quarter · Q3
Issues related to the implementation of H.R. 1, the One Big Beautiful Bill Act (PL 119-21). Legislative proposals on tax simplification, tax reform, and technical tax changes, including H.R.5349, the Taxpayer Assistance and Service Act.
Issues related to defining accounting as STEM education, including H.R. 2911 - the Accounting STEM Pursuit Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABBVIE INC. via MARSHALL & POPP, LLC
2026 · third_quarter · Q3
Issues related to the 340B drug discount program. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ABBOTT LABORATORIES via MARSHALL & POPP, LLC
2026 · third_quarter · Q3
Proposals related to colorectal cancer screening.
Issues related to TRICARE coverage of diabetes management devices.
H.R.3512/S.1821 - Tackling Predatory Litigation Funding Act.
VERTEX PHARMACEUTICALS INCORPORATED via MARSHALL & POPP, LLC
2026 · second_quarter · Q2
Issues related to tariff and trade policy.
Issues related to pain management, including S.475/H.R. 1227 - Alternatives to PAIN Act. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE, White House Office
SUN PHARMACEUTICAL INDUSTRIES, INC. via MARSHALL & POPP, LLC
2026 · second_quarter · Q2
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SANOFI U.S. SERVICES, INC. via MARSHALL & POPP, LLC
2026 · second_quarter · Q2
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
Issues related to tariff and trade policy.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via MARSHALL & POPP, LLC
2026 · second_quarter · Q2
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
PFIZER, INC. via MARSHALL & POPP, LLC
2026 · second_quarter · Q2
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
Issues related to vaccine excise taxes and the Vaccine Injury Compensation Fund.
PERSONAL CARE PRODUCTS COUNCIL via MARSHALL & POPP, LLC
2026 · second_quarter · Q2
Issues related to regulation of cosmetics, including the implementation of the Modernization of Cosmetics Regulation Act as enacted as part of the Consolidated Appropriations Act (PL 117-328).
Issues related to regulation of cosmetics, including sunscreen regulation and the implementation of the Modernization of Cosmetics Regulation Act as enacted as part of the Consolidated Appropriations Act (PL 117-328). Issues related to the regulation of over-the-counter products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JP MORGAN CHASE HOLDINGS, LLC via MARSHALL & POPP, LLC
2026 · second_quarter · Q2
Issues related to electronic credit transaction processing.
Filing targets: SENATE
JAZZ PHARMACEUTICALS, INC. AND ITS SUBSIDIARIES, INCLUDING GREENWICH BIOSCIENCES via MARSHALL & POPP, LLC
2026 · second_quarter · Q2
Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the regulation of hemp-derived cannabinoids.
Issues related to tariff and trade policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE
GRAIL, INC. via MARSHALL & POPP, LLC
2026 · second_quarter · Q2
Issues related to cancer screening, including the implementation of Section 6221 of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GOOGLE CLIENT SERVICES LLC via MARSHALL & POPP, LLC
2026 · second_quarter · Q2
Issues related to the World Trade Organization and digital trade rules. S.1705 - Chip Security Act.
Regulation of online advertising.
Issues related to discriminatory foreign tax regimes.
GLAXOSMITHKLINE via MARSHALL & POPP, LLC
2026 · second_quarter · Q2
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the 340B program. Issues related to FDA regulation of pharmaceuticals.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENENTECH, INC. via MARSHALL & POPP, LLC
2026 · second_quarter · Q2
Issues related to tariff and trade policy.
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
FGA ACTION, INC via MARSHALL & POPP, LLC
2026 · second_quarter · Q2
Issues related to the federal budget.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FEDERATION OF AMERICAN HOSPITALS via MARSHALL & POPP, LLC
2026 · second_quarter · Q2
Issues related to the extension of enhanced Affordable Care Act insurance subsidies.
Issues related to Medicaid funding. Issues related to site-neutral payment policies and hospital price transparency provisions. Issues related to health care cybersecurity, rural health extenders, telehealth and drug shortages.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via MARSHALL & POPP, LLC
2026 · second_quarter · Q2
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. Issues related to the 340B program.
Issues related to treatments for Alzheimers therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DAIICHI SANKYO, INC. via MARSHALL & POPP, LLC
2026 · second_quarter · Q2
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
Issues related to tariff and trade policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE
CURIE BIO OPERATIONS, LLC via MARSHALL & POPP, LLC
2026 · second_quarter · 2T
Issues related to the development, testing, and approval of pharmaceutical products.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CSL BEHRING via MARSHALL & POPP, LLC
2026 · second_quarter · Q2
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to regulation of pharmaceuticals. H.R.1476-Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act).
Issues related to tariff and trade policy.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE
BRISTOL-MYERS SQUIBB COMPANY via MARSHALL & POPP, LLC
2026 · second_quarter · Q2
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the 340B program. Issues related to FDA regulation of pharmaceuticals.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRIDGEBIO PHARMA via MARSHALL & POPP, LLC
2026 · second_quarter · Q2
Issues related to pharmaceutical manufacturing, drug pricing, and orphan drugs. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AMGEN USA INC. via MARSHALL & POPP, LLC
2026 · second_quarter · Q2
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R.1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
ALTRIA CLIENT SERVICES via MARSHALL & POPP, LLC
2026 · second_quarter · Q2
Discussions regarding the FDAs need to urgently implement a compliance and enforcement plan to address and prohibit the importation and sale of illicit flavored, disposable electronic nicotine delivery system (ENDS) products. Issues related to federal excise taxes and the taxation of tobacco products. Issues related to FDA approval of tobacco products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AICPA ASSOCIATION OF INTERNATIONAL CERTIFIED PROFESSIONAL ACCOUNTANTS via MARSHALL & POPP, LLC
2026 · second_quarter · Q2
Issues related to defining accounting as STEM education, including H.R. 2911 - the Accounting STEM Pursuit Act.
Issues related to the implementation of H.R. 1, the One Big Beautiful Bill Act (PL 119-21). Legislative proposals on tax simplification, tax reform, and technical tax changes.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AIRPORTS COUNCIL INTERNATIONAL - NORTH AMERICA via MARSHALL & POPP, LLC
2026 · second_quarter · Q2
Issues related to airport infrastructure financing, and the use of fluorinated firefighting foam at airports. Issues related to air traffic control and facility upgrades. Issues related to airport safety, including S.2175 - Pilot and Aircraft Privacy Act, S.2503 - ROTOR Act, and H.R.7613 - ALERT Act. Issues related to federal permitting reform, including H.R.4776 - SPEED Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABBVIE INC. via MARSHALL & POPP, LLC
2026 · second_quarter · Q2
Issues related to the 340B drug discount program. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ABBOTT LABORATORIES via MARSHALL & POPP, LLC
2026 · second_quarter · Q2
Proposals related to Medicare coverage of continuous glucose monitors. Issues related to cancer diagnostics national coverage determination.
H.R.3512 - Tackling Predatory Litigation Funding Act.
Issues related to TRICARE coverage of diabetes management devices.
GLAXOSMITHKLINE via MARSHALL & POPP, LLC
2026 · first_quarter · Q1
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via MARSHALL & POPP, LLC
2026 · first_quarter · Q1
Issues related to pain management, including S.475/H.R. 1227 - Alternatives to PAIN Act. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office
VERIZON COMMUNICATIONS, INC. via MARSHALL & POPP, LLC
2026 · first_quarter · Q1
Issues related to the expensing of capital investment and research and development expenditures, including implementation of the One Big Beautiful Bill Act (PL 119-21).
Issues related to federal spectrum policy. Issues affecting the telecommunications industry, including broadband infrastructure.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SUN PHARMACEUTICAL INDUSTRIES, INC. via MARSHALL & POPP, LLC
2026 · first_quarter · Q1
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SANOFI U.S. SERVICES, INC. via MARSHALL & POPP, LLC
2026 · first_quarter · Q1
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Issues related to vaccine excise taxes and the Vaccine Injury Compensation Fund.
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via MARSHALL & POPP, LLC
2026 · first_quarter · Q1
Issues related to tariff and trade policy.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
PFIZER, INC. via MARSHALL & POPP, LLC
2026 · first_quarter · Q1
Issues related to tariff and trade policy.
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
PERSONAL CARE PRODUCTS COUNCIL via MARSHALL & POPP, LLC
2026 · first_quarter · Q1
Issues related to regulation of cosmetics, including the implementation of the Modernization of Cosmetics Regulation Act as enacted as part of the Consolidated Appropriations Act (PL 117-328).
Issues related to regulation of cosmetics, including sunscreen regulation and the implementation of the Modernization of Cosmetics Regulation Act as enacted as part of the Consolidated Appropriations Act (PL 117-328). Issues related to the regulation of over-the-counter products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JP MORGAN CHASE HOLDINGS, LLC via MARSHALL & POPP, LLC
2026 · first_quarter · Q1
Issues related to electronic credit transaction processing.
Filing targets: SENATE
JAZZ PHARMACEUTICALS, INC. AND ITS SUBSIDIARIES, INCLUDING GREENWICH BIOSCIENCES via MARSHALL & POPP, LLC
2026 · first_quarter · Q1
Issues related to tariff and trade policy.
Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the regulation of hemp-derived cannabinoids.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE
GRAIL, INC. via MARSHALL & POPP, LLC
2026 · first_quarter · Q1
Issues related to cancer screening, including S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GOOGLE CLIENT SERVICES LLC via MARSHALL & POPP, LLC
2026 · first_quarter · Q1
Competition regulation and antitrust, including issues related to online platforms, self-preferencing, online advertising, and app market access.
Regulation of online advertising.
Issues related to the World Trade Organization and digital trade rules. S.1705 - Chip Security Act.
GENENTECH, INC. via MARSHALL & POPP, LLC
2026 · first_quarter · Q1
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Issues related to tariff and trade policy.
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
FGA ACTION, INC via MARSHALL & POPP, LLC
2026 · first_quarter · Q1
Issues related to the federal budget.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FEDERATION OF AMERICAN HOSPITALS via MARSHALL & POPP, LLC
2026 · first_quarter · Q1
Issues related to Medicaid funding. Issues related to site-neutral payment policies and hospital price transparency provisions. Issues related to health care cybersecurity, rural health extenders, telehealth and drug shortages.
Issues related to the extension of enhanced Affordable Care Act insurance subsidies.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via MARSHALL & POPP, LLC
2026 · first_quarter · Q1
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. Issues related to the 340B program.
Issues related to treatments for Alzheimers therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DAIICHI SANKYO, INC. via MARSHALL & POPP, LLC
2026 · first_quarter · Q1
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CURIE BIO OPERATIONS, LLC via MARSHALL & POPP, LLC
2026 · first_quarter · Q1
Issues related to the development, testing, and approval of pharmaceutical products.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CSL BEHRING via MARSHALL & POPP, LLC
2026 · first_quarter · Q1
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to regulation of pharmaceuticals. H.R.1476-Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act).
Issues related to tariff and trade policy.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE
BRISTOL-MYERS SQUIBB COMPANY via MARSHALL & POPP, LLC
2026 · first_quarter · Q1
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRIDGEBIO PHARMA via MARSHALL & POPP, LLC
2026 · first_quarter · Q1
Issues related to pharmaceutical manufacturing, drug pricing, and orphan drugs. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AMGEN USA INC. via MARSHALL & POPP, LLC
2026 · first_quarter · Q1
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Issues related to tariff and trade policy.
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R.1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
ALTRIA CLIENT SERVICES via MARSHALL & POPP, LLC
2026 · first_quarter · Q1
Discussions regarding the FDAs need to urgently implement a compliance and enforcement plan to address and prohibit the importation and sale of illicit flavored, disposable electronic nicotine delivery system (ENDS) products. Issues related to federal excise taxes and the taxation of tobacco products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AIRPORTS COUNCIL INTERNATIONAL - NORTH AMERICA via MARSHALL & POPP, LLC
2026 · first_quarter · Q1
Issues related to airport infrastructure financing, and the use of fluorinated firefighting foam at airports. Issues related to air traffic control and facility upgrades. Issues related to airport safety, including S.2175 - Pilot and Aircraft Privacy Act, S.2503 - ROTOR Act, and H.R.7613 - ALERT Act. Issues related to federal permitting reform, including H.R.4776 - SPEED Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AICPA ASSOCIATION OF INTERNATIONAL CERTIFIED PROFESSIONAL ACCOUNTANTS via MARSHALL & POPP, LLC
2026 · first_quarter · Q1
Issues related to defining accounting as STEM education, including H.R. 2911 - the Accounting STEM Pursuit Act.
Issues related to the implementation of H.R. 1, the One Big Beautiful Bill Act (PL 119-21). Legislative proposals on tax simplification, tax reform, and technical tax changes.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABBVIE INC. via MARSHALL & POPP, LLC
2026 · first_quarter · Q1
Issues related to the 340B drug discount program. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ABBOTT LABORATORIES via MARSHALL & POPP, LLC
2026 · first_quarter · Q1
Proposals related to Medicare coverage of continuous glucose monitors.
Issues related to infant formula, including H.R. 2300 - To ensure national uniformity with respect to certain requirements relating to preterm infant formula.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLAXOSMITHKLINE via MARSHALL & POPP, LLC
2026 · first_quarter · RR
Issues related to pharmaceutical manufacturing, drug pricing, trade and tariffs.
Issues related to pharmaceutical manufacturing, drug pricing, trade and tariffs.
DAIICHI SANKYO, INC. via MARSHALL & POPP, LLC
2026 · first_quarter · RR
Issues related to pharmaceutical manufacturing and drug pricing. Issues related to trade and tariffs.
Issues related to pharmaceutical manufacturing and drug pricing. Issues related to trade and tariffs.
BRISTOL-MYERS SQUIBB COMPANY via MARSHALL & POPP, LLC
2026 · first_quarter · RR
Issues related to pharmaceutical manufacuring. Drug pricing. Trade and tariffs.
Issues related to pharmaceutical manufacuring. Drug pricing. Trade and tariffs.
SUN PHARMACEUTICAL INDUSTRIES, INC. via MARSHALL & POPP, LLC
2026 · first_quarter · RR
Issues related to pharmaceutical manufacturing. Drug pricing. Trade and tariffs.
Issues related to pharmaceutical manufacturing. Drug pricing. Trade and tariffs.
CURIE BIO OPERATIONS, LLC via MARSHALL & POPP, LLC
2026 · first_quarter · RR
Issues related to the development, testing, and approval of pharmaceutical products.
VERTEX PHARMACEUTICALS INCORPORATED via MARSHALL & POPP, LLC
2025 · fourth_quarter · Q4
Issues related to pain management, including S.475/H.R. 1227 - Alternatives to PAIN Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office
VERIZON COMMUNICATIONS, INC. via MARSHALL & POPP, LLC
2025 · fourth_quarter · Q4
Issues related to federal spectrum policy. Issues affecting the telecommunications industry, including broadband infrastructure.
Issues related to the extension of business tax incentives, including the expensing of capital investment and research and development expenditures.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI U.S. SERVICES, INC. via MARSHALL & POPP, LLC
2025 · fourth_quarter · Q4
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via MARSHALL & POPP, LLC
2025 · fourth_quarter · Q4
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
PFIZER, INC. via MARSHALL & POPP, LLC
2025 · fourth_quarter · Q4
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
PERSONAL CARE PRODUCTS COUNCIL via MARSHALL & POPP, LLC
2025 · fourth_quarter · Q4
Issues related to regulation of cosmetics, including sunscreen regulation and the implementation of the Modernization of Cosmetics Regulation Act as enacted as part of the Consolidated Appropriations Act (PL 117-328). Issues related to the regulation of over-the-counter products, including H.R.4273/S.2292, Over-the-Counter Monograph Drug User Fee Amendments, and H.R.5371, Continuing Appropriations and Extensions Act, 2026.
Issues related to regulation of cosmetics, including the implementation of the Modernization of Cosmetics Regulation Act as enacted as part of the Consolidated Appropriations Act (PL 117-328).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JP MORGAN CHASE HOLDINGS, LLC via MARSHALL & POPP, LLC
2025 · fourth_quarter · Q4
Issues related to electronic credit transaction processing.
Filing targets: SENATE
JAZZ PHARMACEUTICALS, INC. AND ITS SUBSIDIARIES, INCLUDING GREENWICH BIOSCIENCES via MARSHALL & POPP, LLC
2025 · fourth_quarter · Q4
Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the regulation of hemp-derived cannabinoids, including H.R.4121/S.2256 - FY26 Agriculture, FDA and Related Agencies Appropriations, and H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026. H.R.946 - ORPHAN Cures Act.
Issues related to tariff and trade policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE
HOUSE RX, INC. via MARSHALL & POPP, LLC
2025 · fourth_quarter · Q4
Issues related to H.R.2484 - Seniors Access to Critical Medications Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRAIL, INC. via MARSHALL & POPP, LLC
2025 · fourth_quarter · Q4
Issues related to cancer screening, including S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GOOGLE CLIENT SERVICES LLC via MARSHALL & POPP, LLC
2025 · fourth_quarter · Q4
Competition regulation and antitrust, including issues related to online platforms, self-preferencing, online advertising, and app market access.
Issues related to online consumer protection.
Regulation of online advertising.
GENENTECH, INC. via MARSHALL & POPP, LLC
2025 · fourth_quarter · Q4
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
FGA ACTION, INC via MARSHALL & POPP, LLC
2025 · fourth_quarter · Q4
Issues related to the federal budget.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FEDERATION OF AMERICAN HOSPITALS via MARSHALL & POPP, LLC
2025 · fourth_quarter · Q4
Issues related to Medicaid funding. Issues related to site-neutral payment policies and hospital price transparency provisions. Issues related to health care cybersecurity, rural health extenders, telehealth and drug shortages, including H.R.5371, Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026.
Issues related to the extension of enhanced Affordable Care Act insurance subsidies, including S.3385, Lower Health Care Costs Act; S. 3386, Health Care Freedom for Patients Act of 2025; H.R.6703, Lower Health Care Premiums for All Americans Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via MARSHALL & POPP, LLC
2025 · fourth_quarter · Q4
Issues related to treatments for Alzheimers therapeutics.
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. Issues related to the 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CSL BEHRING via MARSHALL & POPP, LLC
2025 · fourth_quarter · Q4
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to regulation of pharmaceuticals. H.R.1476-Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act).
Issues related to tariff and trade policy.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE
BRIDGEBIO PHARMA via MARSHALL & POPP, LLC
2025 · fourth_quarter · Q4
Issues related to pharmaceutical manufacturing, drug pricing, and orphan drugs. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to discriminatory foreign tax regimes.
Issues related to online consumer protection.
Competition regulation and antitrust, including issues related to online platforms, self-preferencing, online advertising, and app market access.
Issues related to artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tariff and trade policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to tariff and trade policy.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE
Proposals related to tariffs on products imported into the United States.
Issues related to infant formula, including H.R. 2300 - To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and S.4940 - Specialized Infant Formula Act.
Proposals related to Medicare coverage of continuous glucose monitors. Issues related to cancer diagnostics national coverage determination.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to vaccine excise taxes and the Vaccine Injury Compensation Fund.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE
Issues related to tariff and trade policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE
Issues related to tariff and trade policy.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE
Issues related to online consumer protection.
Competition regulation and antitrust, including issues related to online platforms, self-preferencing, online advertising, and app market access.
Issues related to artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to tariff and trade policy.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE
Issues related to infant formula, including H.R. 2300 - To ensure national uniformity with respect to certain requirements relating to preterm infant formula.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to tariff and trade policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE
Issues related to vaccine excise taxes and the Vaccine Injury Compensation Fund.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE
Issues related to online consumer protection.
Issues related to artificial intelligence.
Issues related to discriminatory foreign tax regimes.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE
Issues related to tariff and trade policy.
Issues related to vaccine excise taxes and the Vaccine Injury Compensation Fund.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE
Issues related to tariff and trade policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE
Issues related to tariff and trade policy.
Issues related to vaccine excise taxes and the Vaccine Injury Compensation Fund.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE
Issues related to artificial intelligence.
Issues related to the World Trade Organization and digital trade rules. S.1705 - Chip Security Act.
Issues related to discriminatory foreign tax regimes.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tariff and trade policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE